tradipitant

Small molecule

Also known as VLY-686

Approvedregulatory verdict

Evidence outlook

Approved: NEREUS is indicated for the prevention of vomiting induced by motion in adults. (FDA)

This approval is for an indication outside this terminal's covered markets; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also approved (1)
US
  • NEREUS is indicated for the prevention of vomiting induced by motion in adults.
Product first approved 2025Outside this platform's coverageFDA label
Featured evidence outside this drug's tracked markets:NCT04327661 · Motion Sickness · Phase 3 · met primary endpoint · Reliable signalNCT05903924 · Motion Sickness · Phase 3 · met primary endpoint · Reliable signal

Result from the sponsor's press release; no peer-reviewed publication of this trial was found.

Source for the program status

Company guidance: data expected by end of 2026 (Vanda Pharmaceuticals, 5 Aug 2026). “Results for three Phase III clinical trials expected by end of 2026: NEREUS™ (tradipitant) in vomiting in GLP-1 ,” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Gastroparesis
NCT06836557 · Vanda Pharmaceuticals
2024-01-09 – 2026-03-30 · Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
What this study did
Other / comorbidity
NCT06138613 · Vanda Pharmaceuticals
2023-02-27 – 2027-12-30 · Motion Sickness
What this study did
NCT07446439 · Vanda Pharmaceuticals
2026-03-27 – 2026-12-01 · Nausea and Vomiting, Obesity
What this study did
NCT05903924 · Vanda Pharmaceuticals
2023-09-09 – 2024-04-24 · Motion Sickness
What this study did
NCT04327661 · Vanda Pharmaceuticals
2021-11-15 – 2023-04-12 · Motion Sickness
What this study did
NCT04140695 · Vanda Pharmaceuticals
2019-10-21 – 2020-10-14 · Atopic Dermatitis
What this study did
NCT04326426 · Vanda Pharmaceuticals
2020-04-13 – 2020-08-31 · Coronavirus Infection
What this study did
Phase 2 (6)
Gastroparesis
NCT02970968 · Vanda Pharmaceuticals
2016-11 – 2018-12 · Gastroparesis
What this study did
Other / comorbidity
NCT05653310 · Xiao Jing (Iris) Wang
2023-02-09 – 2027-03 · Functional Dyspepsia
What this study did
NCT06804603 · Vanda Pharmaceuticals
2025-02-25 – 2025-10-06 · Obesity
What this study did
NCT03772340 · Vanda Pharmaceuticals
2018-12-20 – 2019-06-27 · Motion Sickness
What this study did
NCT02651714 · Vanda Pharmaceuticals
2016-01-19 – 2017-08-04 · Atopic Dermatitis
What this study did
NCT02004041 · Vanda Pharmaceuticals
2013-12-10 – 2015-02-19 · Treatment-resistant Pruritus Associated With Atopic Dermatitis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT04849559 · Vanda Pharmaceuticals
2021-02-01 – 2021-09-24 · Healthy Volunteer
What this study did
Phase 1 (2)
Other / comorbidity
NCT02621385 · Vanda Pharmaceuticals
2015-11 – 2016-02 · Healthy Volunteers
What this study did
NCT01919944 · Vanda Pharmaceuticals
2013-08 – 2013-11 · Pruritus
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow tradipitant to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 3Nausea and Vomiting, ObesityRecruiting
Est. primary completion 2026-12-01 · NCT07446439 · CT.gov ↗
What to watch
2027 (2)
March 2027 (1)
Phase 2Functional DyspepsiaEnrolling by invitation
Est. primary completion 2027-03 · NCT05653310 · CT.gov ↗
What to watch
September 2027 (1)
Phase 3Motion SicknessActive not recruiting
Est. primary completion 2027-09-30 · NCT06138613 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(7)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026Topline resultPhase III Study 3601 topline results in GLP-1-induced vomiting
26 March 2026Complete response letterFDA denies hearing request and refuses to approve NDA 218489 for gastroparesis
US, FDA · FDA · Source ↗
30 December 2025ApprovalFDA approves NEREUS (tradipitant) for motion-induced vomiting
US, FDA · Source ↗
30 December 2025FDA action dateFDA PDUFA target date for tradipitant in motion sickness
US, FDA · Source ↗
17 November 2025Topline resultPositive topline results for tradipitant in GLP-1 induced nausea and vomiting
18 September 2024Complete response letterFDA complete response letter on the tradipitant NDA for gastroparesis
US, FDA · FDA · Source ↗
September 2024Complete response letterFDA issues CRL for tradipitant NDA
US, FDA · Source ↗